Evaxion A/S
EVAX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001828253
No open-market purchases or sales by Evaxion A/S insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $4.93M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Evaxion A/S changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 7 | 12 | +5 |
| Shares | 340.3K | 1.08M | +737.5K (+216.7%) |
| Value | $3.28M | $4.76M | +$1.49M (+45.3%) |
New holders (7)
Institutions that held Evaxion A/S at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Luminus Management LLC | 777,990 | $3.44M | 0.81% |
| Two Sigma Investments, LP | 40,919 | $181.0K | 0.00% |
| Renaissance Technologies LLC | 20,270 | $90.0K | 0.00% |
| Susquehanna International Group, LLP | 15,090 | $67.0K | 0.00% |
| Steward Partners Investment Advisory, LLC | 1,000 | $4.00K | 0.00% |
| Tower Research Capital LLC (TRC) | 427 | $2.00K | 0.00% |
| Simplex Trading, LLC | 400 | $1.00K | 0.00% |
Sold out (2)
Institutions that held Evaxion A/S at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Maven Securities LTD | 222,806 | $2.15M |
| Credit Suisse AG | 40,315 | $389.0K |